Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.73 |
| ▸ | RARB | P10826 | 3/20 | 0.69 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.65 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.62 |
| ▸ | THRA | P10827 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968275 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B | |
| SCHEMBL2039230 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B | |
| SCHEMBL15177361 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B | |
| SCHEMBL10497781 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B | |
| SCHEMBL10499017 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B | |
| SCHEMBL762326 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B | |
| SCHEMBL2039972 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B | |
| SCHEMBL10497130 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B | |
| SCHEMBL2035476 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B | |
| SCHEMBL498865 | 1.00 | GAA (0.86) | GAAL3MBTL1TP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11796856-B1 | Organic solid crystals having helical structures formed using cholesteric liquid crystals | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-2791112-B1 | CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES | CELGENE INT II SÀRL (CH) | 2020-09-23 | — | — | EP | disclosed |
| EP-2791112-B1 | CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES | CELGENE INT II SÀRL (CH) | 2020-09-23 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| EP-2350119-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | Merlion Pharmaceuticals Pte Ltd. (SG) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
| WO-2009133831-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2009-11-05 | — | — | WO | disclosed |
| US-7270858-B2 | Inclined optical compensation film, method for producing the same and liquid crystal display including the same | NITTO DENKO CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-0923529-B1 | SUBSTITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER AG (US) | 2001-09-19 | — | — | EP | disclosed |
| EP-0923529-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5863915-A | ENZYME INHIBITORS FOR BONES AND JOINTS | BAYER CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1997043237-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0328669-A1 | CHALCONE DERIVATIVE COMPOUNDS | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | GAA 3377/4885L3MBTL1 4715/4885TP53 4718/4885 |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | GAA 1148/4885L3MBTL1 690/4885TP53 3875/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | GAA 3575/4885L3MBTL1 579/4885TP53 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.